Uremic toxins: New aspects

Journal of Nephrology

Volumn 13, Issue 3 SUPPL., 2000, Pages

  Hörl, Walter H ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dialysis; End stage renal disease; Uremic retention solutes; Uremic toxins

Indexed keywords

ARGININE; DRUG DERIVATIVE; HOMOCYSTEINE; LIPOPROTEIN; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; TOXIN;

CHEMISTRY; HUMAN; METABOLISM; MOLECULAR WEIGHT; PHYSIOLOGY; REVIEW; UREMIA;

ARGININE; HOMOCYSTEINE; HUMANS; LIPOPROTEINS; MOLECULAR WEIGHT; TOXINS, BIOLOGICAL; UREMIA;

EID: 0034324164     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-31.
2. Vallance P, Leone A, Calver A, collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 (suppl 12): S60-S62.
3. Faraci FM, Brian JDJ, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269: H1522-7.
4. Segarra G, Medina P, Ballester RM, Lluch P, Aldasoro M, Vila JM, Lluch S, Pelligrini DA. Effects of some guanidino compounds on human cerebral arteries. Stroke 1999; 30: 2206-10.
5. McDermott JR. Studies on the catabolic of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976; 154: 179-84.
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
7. Joannides R, Bakkali EH, Leroy FL, Rivault O, Godin M, Mooere N, Fillastre JP, Thuillez C. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 1997; 12: 2623-8.
8. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997; 52: 468-72.
9. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53: 1068-77.
10. Kielstein JT, Bode-Böger SM, Fröhlich JC, Haller HH, Böger RH. Relationship of ADMA to dialysis treatment and atherosclerosis disease. Kidney Int (in press)
11. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Fröhlich JC. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600.
12. Schmidt RJ, Domico J, Samsell LS, Yokota S, Tracy TS, Sorkin MI, Engels K, Baylis C. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999; 34: 228-34.
13. Kielstein JT, Lonnemann G, Bode-Böger SM, Fröhlich JC, Böger RH. Comparison of dialyzer clearances and quantitative measurement of total removal of the endogenous nitric oxide inhibitor ADMA using a batch dialysis system. J Am Soc Nephrol 1999; 10: 191 A.
14. Anderstam B, Katzarski K, Bergström J. Serum levels of Ng, Ngdimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients.J Am Soc Nephrol 1997; 8: 1437-42.
15. Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999; 276: F794-7.